AANS and CNS Support Proposed Breakthrough Device Coverage Policy

On Aug. 28, the AANS and the CNS submitted comments to the Centers for Medicare & Medicaid Services responding to a proposal to cover devices cleared under the Food and Drug Administration’s (FDA) Breakthrough Device pathway. The neurosurgery groups expressed support for the new CMS coverage pathway, Transitional Coverage for Emerging Technologies, urging the agency to implement the program in a way that will safeguard high-quality and real-world evidence development for the technologies selected.